GlassScriptPhysician profile
Jencymol Mathew
NPI 1457008872
$2,086.96
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,139 · 2023: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.92 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.16 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $198.88 | 2022-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Ironshore Pharmaceuticals INC. | $169.31 | 2022-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $148.19 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.35 | 2022-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $118.22 | 2022-2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $102.53 | 2022-2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $83.80 | 2022-2023 | Trintellix |
| Lundbeck LLC | $81.01 | 2022-2023 | Rexulti |
| Neos Therapeutics, LP | $79.58 | 2022 | |
| Corium, LLC | $77.48 | 2022-2023 | Azstarys |
| Alkermes, INC. | $51.31 | 2022-2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $44.89 | 2022-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $35.03 | 2022-2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.44 | 2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $15.86 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jencymol Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.